Showing results (131-140 of 464) with videos related to

Sort By:
Pageof 47
Molecular Pharmacology|August 1, 1989
Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell lineG Batist, S Torres-Garcia, J M Demuys, et al.
Molecular Pharmacology|September 1, 1990
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cellsV Skalski, D B Yarosh, G Batist, et al.
The Journal of Biological Chemistry|November 25, 1986
Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cellsG Batist, A Tulpule, B K Sinha, et al.
Journal of Molecular Endocrinology|February 15, 2001
Regulation of the gap junction connexin 43 gene by androgens in the prostateH T Huynh, L Alpert, D W Laird, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2010
Quality of life during the course of cancer treatment in older newly diagnosed patients. Results of a prospective pilot studyM T E Puts, J Monette, V Girre, et al.
Critical Reviews in Oncology/Hematology|November 27, 2009
Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot studyM T E Puts, J Monette, V Girre, et al.
Critical Reviews in Oncology/Hematology|May 12, 2009
Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: A qualitative studyM T E Puts, V Girre, J Monette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levelsG Batist, F Patenaude, P Champagne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Mutation Research|May 1, 1995
Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistanceJ Bramson, A McQuillan, R Aubin, et al.
Pageof 47